



Background


- The compound in question (no compound number or name reported) entered clinical trials for treatment of reduced estrogen levels in post-menopausal women
- Symptoms of post-menopause can include depression, insomnia, dry skin, weight changes, and hair loss
- Historically, these symptoms have been treated using hormone-replacement therapy (HRT), but recent studies showed that long-term HRT may cause increased risk of cardiovascular disease, stroke, and cancer
- By selectively targeting estrogen receptor β , researchers hoped to avoid some of the risks associated with traditional HRT




Discovery Route




Early Strategy




Revised Retrosynthesis



Model Study





Final Route for Clinical Studies (Multikilogram Scale)

